Chinese COVID-19 vaccine developer Clover files for IPO
Clover Biopharmaceuticals, a Chinese pre-revenue drug developer that has raised $315 million across several funding rounds since 2011, has filed for a Hong Kong IPO.
The company claims to be a leading COVID-19 vaccine developer and potentially one of the first companies to commercialize a protein-based COVID-19 vaccine globally. Its vaccine candidate can survive at...
More on Greater China
Latest News
VC investors primed for exit with China Youzan reorganisation
Hillhouse Capital and Matrix Partners China are set for liquidity events after China Youzan, an e-commerce software-as-a-service (SaaS) business listed in Hong Kong, agreed to take full control of its key subsidiary for HKD 2.6bn (USD 334.5m).
Goldman backs Japan taxi-hailing player Go
Goldman Sachs Asset Management (GSAM) has committed JPY 10bn (USD 75m) in Series D funding to Go Inc, operator of a Japan-based taxi-hailing app.
AVCJ daily bulletin returns May 29
AVCJ’s daily bulletin will not be published on May 26 due to a public holiday in Hong Kong.
Digital bank Tyme wins funding for SE Asia, Africa expansion
Tyme Group, an emerging markets-focused digital banking group with operations in the Philippines and South Africa, has raised USD 77.8m in pre-Series C funding. A portion of the proceeds will be used for expansion into other markets in Southeast Asia.